VBL Therapeutics enrolls first patients in Phase 2 metastatic colorectal cancer trial

VBL Therapeutics

VBL Therapeutics (NASDAQ:VBLT) enrolled the first two patients in its Phase 2 trial evaluating VB-111, in combination with nivolumab, for the treatment of metastatic colorectal cancer.

VB-111 is an adenovirus that carries a transgene for the Fas-TNFR-1. Administered intravenously once every six-to-eight weeks, VB-111 targets endothelial cells within the tumor vasculature, potentially making tumors visible to the immune system. 

“Colon cancer is one of the most common cancers worldwide, but immune-based approaches in gastrointestinal cancers have unfortunately been largely unsuccessful,” Dr. Tim Greten, the study’s principal investigator, said in a statement. 

“The goal of this Phase 2 study is to investigate whether priming with VB-111, followed by the addition of nivolumab, may induce an anti-tumor immune response in metastatic colorectal cancer, for which there remains a major unmet need,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.